Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5945010 | 0.77 | BACE1 (0.50) | MAPTBACE1 | |
| SCHEMBL5359537 | 0.74 | ADRB1 (0.49) | HTR1A | |
| Hydrochloric Acid SCHEMBL5361148 | 0.74 | ADRB1 (0.48) | HTR1A | |
| SCHEMBL5364887 | 0.74 | DRD2 (0.55) | MAPTTDP1L3MBTL1HTR1A | |
| SCHEMBL5357397 | 0.72 | SMN1; SMN2 (0.44) | MEN1KMT2AMAPTBACE1L3MBTL1 | |
| SCHEMBL4558300 | 0.71 | SLC6A9 (0.44) | HTR1A | |
| SCHEMBL30881604 | 0.71 | ADRA2C (0.45) | MEN1KMT2AMAPTPOLBGAA | |
| SCHEMBL17491559 | 0.71 | ADRA2C (0.45) | MEN1KMT2AMAPTPOLBGAA | |
| SCHEMBL21900286 | 0.71 | SLC6A7 (0.36) | MEN1KMT2AMAPTHTR1APOLB | |
| SCHEMBL2327343 | 0.70 | RBP4 (0.37) | MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7229984-B2 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-06-12 | — | — | US | disclosed |
| US-20060154914-A1 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154914-A1 | Dibenzoxazepinone derivatives and uses thereof | HTR6, BDKRB1, HTR7 | MEN1 1588/4885KMT2A 1848/4885CHRM2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.